Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Reiterated by Guggenheim

Guggenheim reaffirmed their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Other analysts have also recently issued research reports about the company. Jonestrading restated a hold rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a report […]

Related Keywords

United States ,Stifel Nicolaus ,Deutsche Bank ,Jefferies Financial Group ,Deciphera Pharmaceuticals Price Performance ,Deciphera Pharmaceuticals Inc ,Analyst Recommendations For Deciphera Pharmaceuticals ,Hedge Funds Weigh In On Deciphera Pharmaceuticals ,Deciphera Pharmaceuticals ,News Ratings For Deciphera Pharmaceuticals Daily ,Panagora Asset Management Inc ,Barclays ,Deerfield Management Companylp Series ,Free Report ,Financial Group ,Get Free Report ,Asset Management ,Forest Capital Management ,Deciphera Pharmaceuticals Daily ,Nasdaq Dcph ,Dcph ,Medical ,Reiterated Rating ,Guggenheim ,